An observational study, following a trial, to assess the immunogenicity and safety of standard dose versus fractional doses of COVID-19 vaccines (Pfizer-BioNTech or AstraZeneca) or standard dose Coronavac given as an additional dose after priming with Coronavac or AstraZeneca in healthy adults in Indonesia (Extension)
Outcome
To assess and compare the long-term immune response following fractional versus standard doses of COVID-19 vaccines given as a single additional dose in adults aged 18 years or more in Indonesia, as an observational extension of the parent BCOV-22 trial
Sponsor
Murdoch Children's Research Institute
Date
-
Subjects
591 subjects